CLINICAL TRIALS
At MakatiMed Cancer Institute, clinical trials play a vital role in advancing cancer care by providing patients access to innovative treatments and therapies that are not yet widely available. These trials are carefully designed research studies that evaluate the safety, effectiveness, and potential benefits of new drugs, treatment approaches, and medical technologies. Guided by strict ethical standards and overseen by expert oncologists, researchers, and healthcare professionals, the Institute ensures patient safety while contributing to global medical knowledge. Participation in clinical trials allow patients to play an active role in their treatment journey, gain access to cutting-edge care, and help shape the future of cancer management for generations to come.
CLINICAL TRIAL
A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety Canakinumab versus Placebo as Adjuvant Therapy in Adult Subjects with AJCC/UICC v.8 II-IIIA and IIIB (T>5cmN12) completely resected (R0) Non Small Cell
Lung Cancer (NSCLC)
(CANOPY A)
CACZ885T2301
CLINICAL TRIAL
A Randomized, Double Blind, Placebo-controlled, Phase III study evaluating the efficacy and safety Pembrolizumab plus platinum-based doublet chemotherapy with or without Canakinumab as first line therapy for locally advanced metastatic non-squamous and squamous non-small cell lung cancer subjects
(CANOPY-A)
CLINICAL TRIAL
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil Plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
D822BC00001 ACERTA
CLINICAL TRIAL
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
D933RC00001 (NIAGARA)
CLINICAL TRIAL
A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda (Pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
ICON
CLINICAL TRIAL
A phase 3 randomized, double-blind study of ianalumab (VAY736)
versus placebo in addition to eltrombopag in patients with primary
immune thrombocytopenia (ITP) who had an insufficient response or
relapsed after first line steroid treatment
VAYHIT2
CLINICAL TRIAL
A Master Protocol Phase III, Open-Label, Randomized, Multicentre, Parallel Arm Study to Evaluate the Efficacy and Safety of 1L Trastuzumab Deruxtecan in Combination With Rilvegostomig or Volrustomig vs Pembrolizumab Plus Chemotherapy in Locally Advanced, Unresectable or Metastatic HER2 Overexpressing
Non-squamous NSCLC
CLINICAL TRIAL
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
CLINICAL TRIAL
A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety Canakinumab versus Placebo as Adjuvant Therapy in Adult Subjects with AJCC/UICC v.8 II-IIIA and IIIB (T>5cmN12) completely resected (R0) Non Small Cell
Lung Cancer (NSCLC)
(CANOPY A)
CACZ885T2301
CLINICAL TRIAL
A Randomized, Double Blind, Placebo-controlled, Phase III study evaluating the efficacy and safety Pembrolizumab plus platinum-based doublet chemotherapy with or without Canakinumab as first line therapy for locally advanced metastatic non-squamous and squamous non-small cell lung cancer subjects
(CANOPY-A)
CLINICAL TRIAL
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil Plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
D822BC00001 ACERTA
CLINICAL TRIAL
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil Plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
D822BC00001 ACERTA
CLINICAL TRIAL
A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety Canakinumab versus Placebo as Adjuvant Therapy in Adult Subjects with AJCC/UICC v.8 II-IIIA and IIIB (T>5cmN12) completely resected (R0) Non Small Cell
Lung Cancer (NSCLC)
(CANOPY A)
CACZ885T2301
CLINICAL TRIAL
A Randomized, Double Blind, Placebo-controlled, Phase III study evaluating the efficacy and safety Pembrolizumab plus platinum-based doublet chemotherapy with or without Canakinumab as first line therapy for locally advanced metastatic non-squamous and squamous non-small cell lung cancer subjects
(CANOPY-A)
CLINICAL TRIAL
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil Plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
D822BC00001 ACERTA
CLINICAL TRIAL
A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil Plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
D822BC00001 ACERTA
